Latest News

March 8, 2023

The ComboMATCH patient registration trial and three treatment trials are now open

February 27, 2023

The TAILORx trial continues to provide reassurance that many women with early breast cancer can safely forego chemotherapy

February 23, 2023

A focus on the DREAMseq trial reveals data-driven clinical insights into the selection of first-line treatment options for patients with BRAF-mutated metastatic melanoma

February 15, 2023

A participant in the E1910 trial shares her experience in a Penn Medicine feature story with her hematologist, Dr. Selina Luger

February 15, 2023

ASCO Living Guideline says ‘no’ to anti-VEGF-chemo combo in non-small cell lung cancer without driver alterations, based on data from the E5508 trial

February 10, 2023

The January/February 2023 News from ECOG-ACRIN blog is now available

February 10, 2023

ECOG-ACRIN announces the Remarkable Mentor to Women in Oncology Award (nominations are due March 9)

February 9, 2023

The application period is now open for Spring Meeting Attendance Awards for minority trainees

February 6, 2023

Ongoing Trial: The INSIGNA clinical trial is testing the timing of immunotherapy alone or with chemotherapy for patients with advanced lung cancer


About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More


Home

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More


ECOG-ACRIN by the Numbers

Home
41

Active Clinical Trials

Home
1400

Participating Institutions

Home
67

International Sites

Home
21000

Individual Members


Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).

ECOG-ACRIN Cancer Research Group